Research progress of radionuclide labeled imaging agents targeting PD-1 and pD-L1 in the diagnosis of tumors
10.3760/cma.j.issn.2095-2848.2019.02.012
- VernacularTitle:核素标记的PD-1与PD-L1显像剂在肿瘤诊断中的研究进展
- Author:
Yansha SUN
1
;
Shaoli SONG
Author Information
1. 上海交通大学医学院附属仁济医院核医学科 200127
- Keywords:
Neoplasms;
Programmed cell death 1 receptor;
Tomography,emission-computed,single-photon;
Positron-emission tomography;
Diagnosis;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(2):108-111
- CountryChina
- Language:Chinese
-
Abstract:
Blocking the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) immune checkpoint axis is a research focus in the field of tumor immunotherapy with remarkable clinical success,but a substantial number of patients do not respond.So it is important to predict the immunotherapy response by evaluating the expression of PD-1 and PD-L1.In order to evaluate tumor load dynamically and stratify responders to PD-1 and PD-L1 inhibitors,a repetitive,noninvasive functional imaging technique,which based on radionuclide labeled imaging agents targeting PD-1 and PD-L1,is needed to locate and quantify the spatiotemporal expression profiles of PD-1 and PD-L1 specifically.
